Pneumococcal vaccine - Tianjin CanSino BiotechnologyAlternative Names: PBPV
Latest Information Update: 18 Jul 2016
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pneumococcal infections
Most Recent Events
- 18 Jul 2016 Preclinical trials in Pneumococcal infections (Prevention) in China (unspecified route)